BTRX-335140 - An Overview
To paraphrase, a trend towards a reduction in LS was observed only from the arm addressed with the highest dose of OCA. In One more state of affairs, specifically non-alcoholic steatohepatitis, clients enrolled from the stage III REGENERATE review with OCA confirmed a major reduction in LS soon after 18 months in the OCA 25 mg group vs. the placebo